| Trial ID: | L3616 |
| Source ID: | NCT00696995
|
| Associated Drug: |
Biphasic Insulin Aspart 30
|
| Title: |
An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment
|
| Acronym: |
Start
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart 30
|
| Outcome Measures: |
Primary: The number of serious adverse drug reactions, including major hypoglycaemic events, at 26 weeks | Secondary: The number of all hypoglycaemic events, at 26 weeks|HbA1c, at 12 weeks and 26 weeks|Fasting plasma glucose at visits, at 12 weeks and 26 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
509
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2007-01
|
| Completion Date: |
2008-09
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-09
|
| Locations: |
Novo Nordisk Investigational Site, Lahti, 15110, Finland
|
| URL: |
https://clinicaltrials.gov/show/NCT00696995
|
